Introduction

Low birthweight is associated with an increased risk of type 2 diabetes [1]. It has been hypothesised that this reflects the effects of poor nutrition of the fetus leading to permanent changes in glucose metabolism [2]. The underlying mechanisms are not clear, but a link between low birthweight and insulin resistance is well documented [3, 4] and an association with low insulin secretion has been reported [5, 6]. Genetic factors contributing to in utero growth retardation and adult diabetes risk have also been implicated [7], suggesting an inherited predisposition to insulin resistance [8]. Less is known about autoimmune diabetes in the context of birthweight; a small but significant link between high birthweight and type 1 diabetes has been documented, most probably reflecting maternal diabetes, affecting both the fetal development and future diabetes risk [9, 10].

Latent autoimmune diabetes in adults (LADA) is an autoimmune form of diabetes with adult onset and slower progression than type 1 diabetes [11]. It may be the second most prevalent type of diabetes in Europe, accounting for 10% of all diabetes in the adult population [12]. Described as a hybrid form of diabetes, LADA also has features of type 2 diabetes as patients tend to be insulin resistant and overweight [11]. The similarities with type 2 diabetes imply that low birthweight may increase the risk of LADA as a result of the same underlying aetiology. The risk of LADA may also, like type 1 diabetes, be related only to high birthweight, reflecting an excess risk associated with diabetes in the mother [13]. To date, no attempts have been made to elucidate the association between birthweight and LADA.

Our aim was to explore the risk of LADA and type 2 diabetes in relation to birthweight, using data from a Swedish population-based study of incident cases of diabetes.

Methods

Study population

We used data from the Epidemiological Study of Risk Factors for LADA and Type 2 diabetes (ESTRID), a population-based case–control study with incident cases (www.ki.se/IMM/ESTRID). The details of ESTRID have been described previously [14]. In short, ESTRID was initiated in 2010, recruiting incident cases of diabetes through diabetes registries in the Swedish counties of Skåne (All New Diabetics in Skåne [ANDIS], http://andis.ludc.med.lu.se/) and Uppsala (All New Diabetics in Uppsala [ANDiU], www.andiu.se/). The aim of these registers is to characterise all incident cases of diabetes according to type, genetic factors and clinical features.

All individuals with incident LADA registered in Skåne (2010–) and Uppsala (2012–) were invited to take part in ESTRID, together with a random sample of people with type 2 diabetes (four per LADA case) and control participants free from diabetes (six per LADA case). The controls were randomly selected via the National Population Registry, which covers the whole population of Skåne and Uppsala (~1.6 million inhabitants). They had to be ≥35 years of age (corresponding to the criteria used to define LADA) and were matched on geographical area (county) and date of participation, i.e. incidence density sampling [15]. All participants in ESTRID between 1 September 2010 and 1 July 2014 with self-reported information on birthweight were eligible for the analyses presented here.

Of the original sample, 44.6% (Skåne) and 45.3% (Uppsala) of participants could recall their birthweight information, including 134 patients with LADA, 350 patients with type 2 diabetes and 603 controls. Those who filled in the questionnaire but did not remember their birthweight (answered ‘I do not know’ to the birthweight question) were excluded from the analysis. The overall response rates for ESTRID were 80% for cases and 66% for controls. Participants gave written informed consent and the study was approved by the Ethical Review Board in Stockholm (reference number 2010/336-31/2).

Assessment of exposure and covariates

A comprehensive questionnaire soliciting a broad range of items on lifestyle, family history and health was sent out by mail to all cases and their matched controls. Patients received the questionnaire close to diagnosis, with careful instructions to report lifestyle habits as they had been before diagnosis.

Birthweight

Information on birthweight was based on self-reports. To validate the self-reported information on birthweight, ESTRID was linked to the Swedish Medical Birth Register. This registry contains information on prenatal and neonatal care for nearly all births in Sweden from 1973 onwards; information on birthweight was collected for all ESTRID participants born in 1973 onwards (n = 112). Of these individuals, 76 (68%), including 16 cases and 60 controls, also had self-reported information on birthweight from the ESTRID questionnaire.

Covariates

The BMI was calculated by self-reported weight and height as kg/m2 and participants were categorised based on WHO criteria as normal weight (BMI < 25 kg/m2), overweight (BMI ≥ 25 kg/m2) and obese (BMI ≥ 30 kg/m2). Detailed information on family history of diabetes was gathered through questions on diabetes in first-degree relatives (mother, father, sister, brother and children) and second-degree relatives (maternal and paternal grandparents, aunts and uncles). Relatives were classed as having type 1 diabetes if they had onset <age 40 and insulin treatment, but were otherwise deemed to have type 2 diabetes. Responders were also asked to report their highest level of education, with the categories elementary, high school and university. Smoking status was collected by questions on smoking habits and respondents were divided into current, former or never smokers. Alcohol intake was assessed through questions on amount and frequency of wine, beer and liquor intake, with participants classed as abstainers, ex-drinkers, or low, moderate or high consumers based on this information. Information on physical activity was obtained by questions on leisure time activity during the preceding year, with four response options ranging from sedentary to very active.

Clinical data and case definition

Patients were diagnosed within the healthcare system of Skåne and Uppsala and registered in the ANDIS (Skåne) and ANDiU (Uppsala) registries. At the time of diagnosis, blood samples from all cases were collected and analysed for glutamic acid decarboxylase antibody (GADA), C-peptide and fasting blood glucose levels at the central laboratory of the university hospital of each county.

Positivity for GADA, which is the most common autoantibody, being present in 90% of all individuals with adult autoimmune diabetes [12], was measured by ELISA, with cut-off ≥10 U/ml, according to the manufacturer’s directions [16]. The values are reported as an index value in relation to standard serum. The assay gives a maximum value of 250 with a cut-off level 10.7 U/ml; when GADA was measured in Ca2+ treated plasma, sensitivity and specificity were estimated as 84% and 98%, respectively [16].

Assessment of C-peptide level was performed using a Cobas e 601 analyser, (Roche Diagnostics, Mannheim, Germany) or IMMULITE 2000 (Siemens Healthcare Diagnostics Products, Llanberis, UK) [17].

For this study, LADA was defined as onset ≥35 years of age, GADA positivity (≥10 U/ml) and C-peptide levels ≥0.3 nmol/l (Cobas e 601) or ≥0.2 nmol/l (IMMULITE). Individuals with onset ≥35 years but who were GADA negative (<10 U/ml) and with C-peptide levels >0.72 nmol/l (Cobas e 601) or >0.6 nmol/l (IMMULITE) were classed as having type 2 diabetes. There is no universal definition of LADA, but this definition is in line with previous reports, except for C-peptide which was used as an indicator of remaining insulin production and a slow ‘latent’ onset. This replaced the commonly used insulin criterion, which is subjective. Via linkage to the ANDIS and ANDiU registries, clinical data from the time of diagnosis were available for all patients who gave consent for this (98.8% of all cases; two LADA cases and four type 2 diabetes cases are missing in these analyses). The HOMA model was used to estimate insulin resistance (HOMA-IR) and beta cell function (HOMA-β) based on fasting plasma glucose and C-peptide [18]. Information from blood samples was not available for the controls in the present study.

Statistical analysis

By means of logistic regression we calculated ORs with 95% CIs for the associations for birthweight, LADA and type 2 diabetes. Conditional logistic regression analysis, matched for date of participation and residential area, was also conducted, but we present only the results from the unmatched analyses as these were in close agreement with those from the matched analyses, but allowed us to use all the available information. The ORs were interpreted as incidence rate ratios, as this case–control study was based on incident cases and controls sampled by incidence density sampling [15].

The ORs were adjusted for age (continuous) and sex (model 1), age, sex and BMI (continuous) (model 2) and age, sex, BMI and family history of diabetes (yes vs no) (model 3). Results from model 3 are presented unless otherwise stated. Information on these covariates was complete for all participants with information on birthweight. Additional adjustment for education, smoking, alcohol and physical activity did not affect the ORs and therefore these variables were not included in the final model. Birthweight was modelled both as a continuous variable (per kg reduction in birthweight) and as a categorical variable divided into low (<3 kg), normal (3–<4 kg) and high (≥4 kg) birthweight. We also modelled birthweight in five categories with reference to the WHO definition of low birthweight (<2.5 kg, 2.5–<3 kg, 3–<3.5 kg, 3.5–<4 kg and ≥4.0 kg) [19]. To determine possible interactions between low birthweight and overweight we calculated the relative excess risk due to interaction (RERI) [20]. In these analyses, birthweight and BMI were dichotomised as low (<3 kg) and high (≥3 kg) birthweight and normal weight (BMI < 25 kg/m2) vs overweight/obesity (BMI ≥ 25 kg/m2). Sensitivity analyses were performed using a higher cut-off for the GADA assay (≥20 U/ml rather than ≥10 U/ml). We also performed separate analyses in which: participants reporting diabetes in the mother were excluded to account for maternal diabetes during pregnancy; and participants born outside Sweden or with immigrant parents were excluded, to check if ethnicity could affect the results. Analyses were performed separately for individuals older than 60 years as we could not validate self-reported birthweight in higher age groups and participants’ recall may have been less reliable.

Two-sided p values were calculated using χ 2 (proportion), Student’s t (mean) and Kruskal–Wallis (median) tests. All statistical calculations were performed using the statistical software program SAS version 9.4 (SAS Institute, Cary, NC, USA). Where ORs are reported, the 95% CI are shown in parentheses.

Results

Validity of self-reported birthweight

The correlation between self-reported and registry-based information on birthweight was 0.86 (p < 0.0001). For patients this estimate was 0.91 (p < 0.0001) and for controls 0.83 (p < 0.0001). The self-reporting method had a sensitivity of 90% and 100% specificity for participants with low (<3 kg) birthweight. All patients were correctly classed according to birthweight category (100% sensitivity and 100% specificity), whereas one control with low birthweight was classed incorrectly in the normal weight group (3–<4 kg). With regard to non-responders to the birthweight question, i.e. ESTRID participants not included in the present study population, we compared registry information on birthweight for those with and without self-reported information on birthweight and found that it was similar: 3.44 kg vs 3.45 kg. If we compare register data for the controls with and without self-reported birthweight (n = 81), we find that those without self-reported weight have a slightly higher mean birthweight (3.55 kg vs 3.43 kg).

Characteristics

Controls had the same mean age (54.7 years) as patients with LADA, but were leaner (Table 1) and had a substantially lower prevalence of family history of diabetes. Compared with patients with type 2 diabetes, LADA patients were leaner and younger, had lower levels of C-peptide, poorer beta cell function and were more often on insulin treatment (58.0% vs 4.3%), whereas no difference in insulin resistance was detected. Family history of type 1 diabetes was more frequent in patients with LADA than in those with type 2 diabetes, whereas family history of type 2 diabetes tended to be more common in the latter group. The proportion with low (<3 kg) birthweight was higher in patients with LADA (21.6%) and type 2 diabetes (22.3%) than in controls (14.1%).

Table 1 Characteristics of the participants
Full size table

LADA and birthweight

The risk of LADA was inversely associated with birthweight (Table 2) and increased by 52% (OR 1.52 [95% CI 1.12, 2.08]) with every kg reduction in birthweight. Compared with those with high (≥4 kg) birthweight, the OR for individuals with low (<3 kg) birthweight was estimated as 2.38 (1.23, 4.60). Exclusion of participants reporting maternal diabetes augmented this estimate slightly, OR 2.77 (1.33, 5.78). Sensitivity analysis using a higher cut-off level for the GADA assay (20 U/ml instead of 10 U/ml) indicated similar results, OR 1.49 (1.07, 2.06) per kg birthweight reduction. A finer division of birthweight into five strata indicated a graded trend, with the highest risk of LADA in those weighing less than 2.5 kg at birth, OR 2.90 (1.19, 7.06) compared with individuals weighing ≥4 kg, but an elevated risk was still seen for those with a birthweight between 2.5 and <3 kg, OR 2.14 (1.03, 4.46). As shown in Table 2, adjustments for BMI and family history of diabetes had a minor influence on the risk estimates.

Table 2 ORs for LADA and type 2 diabetes in relation to birthweight
Full size table

Type 2 diabetes and birthweight

The risk of type 2 diabetes increased by 58% for every kg reduction in birthweight (OR 1.58 [1.23, 2.04]) and the OR for low vs high birthweight was estimated as 2.37 (1.37, 4.10). A similar pattern was seen when dividing birthweight into five groups: ORs for those with the lowest weights (<2.5 kg and 2.5–<3 kg) were 2.48 (1.16, 5.28) and 2.32 (1.23, 4.37), respectively, compared with the highest weight group (≥4 kg).

Interaction between low birthweight and adult overweight

The excess risk of LADA was seen primarily in individuals with a combination of overweight and low birthweight (<3 kg) (Fig. 1); OR was estimated as 3.26 (1.69, 6.29) when compared with individuals with high birthweight and normal adult weight. The RERI was estimated as 1.90, but numbers were small and confidence limits wide (95% CI −0.16, 3.96). With regard to type 2 diabetes, the combination of low birthweight and overweight conferred a 40-fold increased risk (OR 39.93 [19.27, 82.71]) for type 2 diabetes (Fig. 2), with the RERI estimated as 25.09 (2.70, 47.49).

Fig. 1
figure 1

ORs for LADA by combinations of birthweight and BMI. The reference is normal weight and birthweight ≥3 kg

Full size image
Fig. 2
figure 2

ORs for type 2 diabetes by combinations of birthweight and BMI. The reference is normal weight and birthweight ≥3 kg

Full size image

Clinical characteristics of patients with high vs low birthweight

Comparing LADA patients with birthweight above and below 3 kg (electronic supplementary material [ESM] Table 1) indicated that those with low birthweight (<3 kg) tended to be more insulin resistant (mean HOMA-IR 9.75 vs 4.73), have better beta cell function (mean HOMA-β, 46.19 vs 31.92), lower median GADA levels (60 vs 222 U/ml) and higher mean BMI (28.0 vs 26.6 kg/m2); however, numbers were small and potential differences not significant. In patients with type 2 diabetes, no clear differences were seen between those with high and low birthweights.

Discussion

We demonstrate that low birthweight is associated with an increased risk of type 2 diabetes [1] and we also show, for the first time, that low birthweight is linked in a similar way to the risk of LADA, with a more than twofold increased risk associated with birthweight below 3 kg compared with 4 kg or more.

The mechanisms behind the relation between birthweight and type 2 diabetes are not fully understood. According to the ‘thrifty phenotype hypothesis’, introduced by Hales and Barker in 1992 [2], in utero malnutrition causes a metabolic programming of thrift that, when met with rapid postnatal growth, leads to insulin resistance and type 2 diabetes [21]. It is possible that the link between LADA and low birthweight reflects the same underlying mechanism, as LADA, like type 2 diabetes, involves insulin resistance [11]. In support of this common mechanism, LADA patients with low birthweight tended to be more type-2-like, with older age at onset and indications of more pronounced insulin resistance, better beta cell function and less autoimmunity. The numbers were, however, small and these results are only suggestive. Still, these findings are in line with previous studies [11, 22] that suggest that the LADA concept is heterogeneous, covering a spectrum ranging from very autoimmune, type-1-like forms to less autoimmune and more insulin-resistant forms, and risk factors may consequently differ. There was nothing to suggest that low birthweight is associated with autoimmunity per se; if anything, LADA patients with low birthweight tended to have lower GADA levels. This is in agreement with previous findings for type 1 diabetes [9, 10] and other autoimmune diseases, including rheumatoid arthritis [23, 24] and multiple sclerosis [25], suggesting an increased risk associated with high, but not low, birthweight.

In the present study, no information on patients with type 1 diabetes was available. However, previous findings based on all Swedish type 1 diabetes patients born in the period 1983–2007 [26] indicate that mean birthweight is higher in this patient group than in LADA patients (3,540 g vs 3,389 g in our sample).

With regard to type 2 diabetes, our results were in accordance with a large number of previous studies [1]. A striking finding was the strong interaction between low birthweight and adult overweight; a 40-fold increased risk was seen in those with a combination of these risk factors. Few previous studies have investigated the influence of the combination of low birthweight and overweight in relation to diabetes, but similar findings are seen in relation to the metabolic syndrome [27] and myocardial infarction [28]. Notably, the combined effect was not as pronounced for LADA but our results did indicate that low birthweight alone is a risk factor for LADA when combined with adult overweight. These findings fit with the thrifty phenotype hypothesis [21], according to which a system permanently programmed for thrift will store body fat rather than grow muscle when exposed to an affluent nutritional intake [29, 30]. From a public health perspective this is potentially important, as it suggests that many cases of diabetes could be prevented in this additionally predisposed group if a healthy weight is maintained.

Our results support the likelihood that environmental rather than genetic factors underlie the association between low birthweight and diabetes; adjustment for family history had limited influence. This is compatible with results from twin studies [31, 32]. Of note, the association between low birthweight and diabetes was strengthened when individuals with diabetes in the mother were excluded. This is to be expected given that maternal hyperglycaemia may manifest in high birthweight, as well as an increased diabetes risk in the offspring [13].

Considerations of the methods

The strengths of this study include a well-defined population, detailed information on a number of potential confounders and access to registry data for validation. The main limitation was the self-reported information on birthweight. The validity of such information is reportedly high [1, 7, 33] and, in particular, we had the opportunity to validate the self-reports against registry data for the younger part of the cohort. The correlation was high (0.86) and the sensitivity and specificity for correctly classifying participants with low birthweight were 90% and 100%, respectively. It is possible that the quality of the self-reports was less accurate for older participants, for whom we did not have access to registry information. On the other hand, several other studies have indicated that the validity of self-reported information on birthweight is high at older ages [1, 7, 33]. In support, we saw an association between low birthweight and LADA when the analyses were restricted to older participants (≥60 years): OR per kg reduction 1.97 (1.15, 3.36).

We could not distinguish children who were small for gestational age from preterm babies. This would have been interesting as previous studies have shown that type 2 diabetes is associated with both being small for gestational age and prematurity per se [34]. Another limitation was that only 44.6% of the original study population provided information on birthweight – the question is whether those who did not know their birthweight differ from those included in the analysis. In this context, it is important to note that response rates were similar among cases and controls and, furthermore, that registry data indicate that mean birthweight was similar in responders and non-responders. Importantly, our findings for type 2 diabetes were in line with numerous previous studies based on registry data [1].

Notably, there is no uniform definition of LADA. Our criteria were consistent with previous reports except for the use of C-peptide, which provides a more objective measure of residual insulin secretion than lack of insulin treatment for 6–12 months after diagnosis, which is often used [11]. One could speculate that false-positive LADA patients, i.e. patients with type 2 diabetes erroneously identified as having LADA, may contribute to similar findings for birthweight. Still, the sensitivity of the GADA assay suggests that such misclassification is minor. Furthermore, raising the cut-off level on the assay did not change the results.

There were clear differences between the two patient groups with regard to a number of clinical characteristics. One concern is whether the birthweight of the controls reflects the birthweight of the population that generated the cases. Controls were randomly selected from the population, but a spurious association may arise if participating controls had higher birthweight than non-participating controls and consequently than the population as a whole. We have no reason to believe that birthweight would be associated with non-participation. It is noteworthy that when we compared the level of education of our controls with that of the general population in Skåne using data from Statistics Sweden, there were no differences: e.g. 32.8% vs 32.9% had a university degree. A strong argument against selection bias is the similarity of our findings to previous reports on type 2 diabetes based on different methods and populations [1].

Although GADA can disappear after prolonged duration of LADA [35], they tend to be more stable than in type 1 diabetes [11]. Our study was based on newly diagnosed cases, which minimises these problems. With regard to generalisability it should be noted that ethnic differences in the association between birthweight and type 2 diabetes have been suggested [1], possibly reflecting differences in the prevalence of maternal diabetes. Worth mentioning is that the proportion born outside Sweden or who were Swedish born with one or two immigrant parents was low in our sample (14.9%) and analyses excluding these individuals did not affect the results.

Conclusions

Low birthweight was associated with an increased risk of LADA as well as of type 2 diabetes. Our findings favour the role of environmental, rather than genetic, explanations for this link. This paper also supports findings from previous studies [36–39] which indicate that LADA, despite its autoimmune features, has an aetiology that, in part, may be similar to that of type 2 diabetes.